#actor #pharma #uk

**GSK** (GlaxoSmithKline) — British multinational pharmaceutical company. Vaccines, specialty medicines, respiratory treatments.

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | GSK (NYSE, LSE) |
| HQ | London, UK |
| CEO | Luke Miels (since Jan 1, 2026) |
| Revenue target | £40B+ by 2031 |
| Focus | Vaccines, oncology, respiratory |

---

## Leadership

| Role | Name | Since |
|------|------|-------|
| CEO | Luke Miels | Jan 2026 |
| Former CEO | [[Emma Walmsley]] | 2017-2025 |

**Emma Walmsley** was first female CEO of a major pharma company. Stepped down Dec 31, 2025. Remains in advisory role through Sep 2026 for geopolitics and new tech.

**Luke Miels** was Chief Commercial Officer. Prior roles at [[AstraZeneca]], [[Roche]], [[Sanofi]]. Base salary: £1.38M.

---

## Recent history

- **2022** — Spun off consumer health business as [[Haleon]] (HLN)
- **2025** — Emma Walmsley announced departure
- **2026** — "Pivotal year" for growth strategy per management

---

## Portfolio

| Area | Products/Focus |
|------|----------------|
| Vaccines | Shingrix (shingles), respiratory vaccines |
| Oncology | Expanding specialty medicines |
| Respiratory | Asthma, COPD treatments |
| HIV | ViiV Healthcare (majority owned JV) |

---

## Board connections

- [[Emma Walmsley]] sits on [[Microsoft]] board

---

## Quick stats

| Metric | Value |
|--------|-------|
| Market cap | ~£65B |
| Employees | ~70,000 |
| R&D spend | ~£6B annually |

*Updated 2026-01-31*

---

## Related

- [[Emma Walmsley]] — former CEO, Microsoft board member
- [[AstraZeneca]] — UK pharma peer
- [[Haleon]] — consumer health spinoff
- [[Pfizer]], [[Merck]], [[Johnson & Johnson]] — pharma peers
